Using RNA nanoparticles to deliver drugs to the back of the eye
RNA Nanosystem for Posterior Eye Drug Delivery
This study is working on a new way to deliver medicine directly to the back of the eye using tiny RNA particles, which could make treatments safer and more effective for people with eye diseases.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Cincinnati NIH-funded |
| Lab location | 1 site (Cincinnati, United States) |
| Project ID | NIH-10747873 on NIH RePORTER |
What this research studies
This research focuses on developing RNA nanoparticles that can effectively deliver therapeutic agents to the posterior segment of the eye, addressing the challenges of instability and toxicity associated with current delivery methods. The approach involves using stable RNA molecules derived from bacteriophage technology, which can carry multiple therapeutic components. By administering these nanoparticles through subconjunctival injection, the research aims to improve drug delivery while minimizing adverse effects. The goal is to create a more effective treatment option for patients with ocular diseases.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients suffering from chronic ocular diseases that require drug delivery to the posterior segment of the eye.
Not a fit: Patients with non-ocular diseases or those who do not require drug delivery to the posterior eye may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer and more effective treatments for various eye disorders.
How similar studies have performed: Previous studies have shown promise in using RNA nanoparticles for drug delivery, indicating potential success for this approach.
Where this research is happening
Cincinnati, United States
- University of Cincinnati — Cincinnati, United States (Active)
Researchers
- Principal investigator: Li, Kevin S. — University of Cincinnati
- Study coordinator: Li, Kevin S.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.